TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Diagnosis of overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-specific counseling frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased motivation to lose weight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical and radiographic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean kitchen level of Bla g 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of kitchens with over 8 U/g of Bla g 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory airflow duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motivation gain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enjoyment of the task
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: identification with SGP as a teammate
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Duration of total mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Direct and indirect health-care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Measurement of urine albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Measurement of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary salbutamol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Everolimus AUC increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge from intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: serum level of CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum levels of cTnT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum levels of H-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADHD symptoms ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of menstrual cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma gonadal steroid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinizing hormone plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Negative affect ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positivity ratios
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug release profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chemotherapy benefit in patients with Luminal A breast tumors
Endpoint domain: Mortality/survival
Primary endpoint: Physical HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regression to NGR
Endpoint domain: Mortality/survival
Primary endpoint: event-free survival to first delivered therapy
Endpoint domain: Mortality/survival
Primary endpoint: total number of delivered shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients with complete relief from symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate after treatment stopped
Endpoint domain: Adverse events/effects
Primary endpoint: seizure freedom rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: withdrawal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: m-YPAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in tcPO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean number of day 2 embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triploid fertilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower UAER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improve renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: M index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low density lipoprotein cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TdR Pase activity in tumor tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1 alpha production in tumor tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF alpha production in tumor tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospital resource consumption costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Virologic response maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine required over 24 hours for analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of aggressive incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients engaging in aggression
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent in seclusion
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of inflammatory mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete response (no emetic episodes and no rescue medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete plus major response (0‐2 emetic episodes and no rescue medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient visual analog scale assessments of nausea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival free from major adverse cardiac events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Specific antibodies increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in alcohol intake and cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular accident (CVA)
Endpoint domain: Mortality/survival
Primary endpoint: Hyperactivity subscale of the Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of reduced vision (best visual acuity 0.5 or worse)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of WHO TD
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of postoperative lymphocysts
Endpoint domain: Adverse events/effects
Primary endpoint: mean bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythropoiesis-stimulating agent (ESA) dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of complete blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of remission in Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from negative remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal aortic reintervention rate
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of postoperative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of exhaust and defecation after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dosage of supplemented Sauteralgyl
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Deficits in executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Problems related to executive dysfunction (Metacognition Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Problems related to executive dysfunction (Global Executive Composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of CD83, CD80 and CD86
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: norepinephrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance rates for IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance rates for IL-1ra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum reductions in systolic/diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 24-h ambulatory SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 24-h ambulatory DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in drinking behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urogenital Distress Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incontinence Impact Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neuropathy grade ≥2
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathy grade ≥3
Endpoint domain: Adverse events/effects
Primary endpoint: probability of being exacerbation free at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean BSCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady state CBF velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean direct medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early Biochemical Disease-Free Survival (BCDF)
Endpoint domain: Mortality/survival
Primary endpoint: Significant improvement in pain relief and functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QLF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in subjective symptoms and objective signs (nodules and cords)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of disease (treatment failure)
Endpoint domain: Adverse events/effects
Primary endpoint: BMI standard deviation scores (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported health and visual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GTN-induced dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRS 0-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of mutant haplotypes associated with SP-resistant parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal sensitivity to thermal stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preprandial gastric relaxation volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satiation scores during the drink test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amount of insulin prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Delay from diagnosis to initiation of insulin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in ApoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Effectiveness of therapeutic ultrasound and spica splint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operation time per repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: combined clinical end points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of norepinephrine and epinephrine in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median cubital vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: improvement in executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical thickening in the lateral occipitotemporal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total colorectal polyp count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful reattachment of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of oil emulsification
Endpoint domain: Adverse events/effects
Primary endpoint: nicotine withdrawal-related negative affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemotransfusion frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum cobalamin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma methylmalonic acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced tics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of free testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean tactile and air blast dentin hypersensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weekly darbepoetin alfa dose requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse neurologic outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: EPO level in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalization frequency
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: general mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Salivary Nitric Oxide Level (SNL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of adenoma identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for identification of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromosomally normal blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Accuracy in discriminating satisfactory from unsatisfactory performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correctly identified unsatisfactory performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net benefits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DF ROM (Dorsiflexion Range of Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TMT completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: program participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: initiation of cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintained cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of preterm infants with a birth weight below 1900g
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Direct costs per preterm birth
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of intraoperative hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients with intraoperative ST segment deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: biochemical recurrence-free survival probability
Endpoint domain: Mortality/survival
Primary endpoint: urinary continence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Visual Analog Scale (PVAS) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in JSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status (CRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in PSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reclassification to a less severe diagnostic category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in global scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total duration of PDPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myoclonus associated with PGB therapy
Endpoint domain: Adverse events/effects
Primary endpoint: mood change after tRNS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean adherence to telemonitoring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: levels of preparedness and competence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Daily increments and cumulative volumes of enteral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of microorganisms detected in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in the onset of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: worst breathlessness severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(insulin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean sputum weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SaO2 saturation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expansion of the maxillary arch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesialization of the posterior anchoring teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of entrapped lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of interventions required to treat malignant pleural effusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficiency in occluding the spermatic vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety (no glue-related complications)
Endpoint domain: Adverse events/effects